Compare AbCellera Biologics Inc (ABCL) vs Chubb Ltd (CB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Chubb Ltd — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Chubb Ltd trades at $355.29 (market cap $139.36B). The key difference: Chubb Ltd is far larger — about 59.3× AbCellera Biologics Inc's market cap, and Chubb Ltd pays a 1.14% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CB | |
|---|---|---|
Market Cap | $2.35B | $139.36B |
Sector | Health | Financials |
52-Week High | $8.12 | $361.17 |
52-Week Low | $2.78 | $265.99 |
Enterprise Value | $1.99B | $160.41B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Chubb (CB) trades at $359.30, down 0.52% on the day but near its 52-week high, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $59.78B in 2025 to projected $61.2B in 2026, and a net income margin of 18.46%. Recent news highlights premium growth and disciplined underwriting as key strengths.
Outlook remains positive with analyst consensus favoring Buy ratings (52.38%) and a price target of $341.90, though risks include catastrophe losses and softer commercial pricing. The stock's valuation at P/E 12.61 offers value, but investors should monitor Q2 2026 earnings due July 22, 2026, for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →
